What is the most important residual risk after achievement of appropriate low-density lipoprotein cholesterol lowering therapy in secondary prevention of Japanese patients?

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Akihiro Endo

Shimane University Faculty of Medicine, Izumo (Japan)

14 More presentations in this session

Presentation thumbnail

Patient characteristics and treatment patterns in patients on lipid-lowering therapies following an acute coronary syndrome in France

Professor E. Bruckert (Paris, FR)

Abstract Slides

Presentation thumbnail

Association of adherence and treatment intensity of lipid-lowering therapy with cardiovascular outcomes and all-cause mortality in very high-risk patients in Germany

Professor I. Ahrens (Cologne, DE)

Presentation thumbnail

Relative fat mass (RFM) is a better predictor of dyslipidemia and metabolic syndrome than body mass index (BMI).

Doctor O. Kobo (Hadera, IL)

Abstract Slides

Presentation thumbnail

Low levels of low density lipoprotein cholesterol and cardiovascular, cancer and all-cause mortality outcomes

Professor K. Sung (Seoul, KR)

Presentation thumbnail

Effects of personalized therapy-effect predictions on statin treatment decisions by patients and physicians: a three-armed, blinded, randomized controlled trial

Ms N. Jaspers (Utrecht, NL)

Access the full session

Session thumbnail

Poster Session 1 - Lipids

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

Lipidomics to fine-tune cardiovascular risk prediction and personalised treatment

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources